Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

Authors
SG Liva, YC Tseng, AM Dauki, MG Sovic, T Vu et al


Lab
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA

Journal
EMBO Molecular Medicine

Abstract
No approved therapy exists for cancer-associated cachexia. Thecolon-26mouse model of cancer cachexia mimics recent late-stage clinical failures of anabolic anti-cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM) GTx-024. The histone deacetylase inhibitor (HDACi) AR-42exhibited anti-cachectic activity in this model. We explored combined SARM/AR-42 therapy as an improved anti-cachectic treatment paradigm. A reduced dose of AR-42provided limited anti-cachectic benefits, but, in combination with GTx-024, significantly improved bodyweight, hindlimb muscle mass, and grip strength versus controls.AR-42suppressed the IL-6/GP130/STAT3signaling axis in muscle without impacting circulating cytokines. GTx-024-mediatedb-catenin target gene regulation was apparent in cachectic mice only when combined with AR-42. Our data suggest cachectic signaling in this model involves catabolic signaling insensitive to anabolic GTx-024therapy and a blockade of GTx-024-mediatedanabolic signaling. AR-42mitigates catabolic gene activation and restores anabolic responsiveness to GTx-024. Combining GTx-024,a clinically established anabolic therapy, with AR-42, a clinically evaluated HDACi, represents a promising approach to improve anabolic response in cachectic patients.

BIOSEB Instruments Used:
Grip strength test (BIO-GS3)

Produits associés

DEMANDE DE PUBLICATION

Merci de votre intérêt pour notre gamme de produits et de votre demande pour cette publication qui vous sera envoyée si l'équipe de recherche et la revue le permettent. Notre équipe commerciale vous contactera dans les plus brefs délais.